Role of Aseptic Measures in Preventing Surgical Site Infections in Skin Biopsy Procedures

Authors

Jauhar Mumtaz Khan

Consultant Dermatologist, Department of Dermatology, PAF Hospital, PAF Base Faisal Karachi

Muhammad Usman Rathore

Consultant Histopathologist, Department of Pathology, Armed Forces Hospital Najran, Saudi Arabia

Moizza Tahir

Consultant Dermatologist Department of Dermatology, CMH Gujranwala

Ali Riaz

Consultant Dermatologist, Department of Dermatology, CMH Malir, Karachi.

Keywords

Skin biopsy, aseptic measures, surgical site infections

Abstract

Objective:

To evaluate the role of aseptic measures in preventing surgical site infections in skin biopsy procedures.

Study Design:

Prospective, observational study.

Place and Duration of Study:

PAF Hospital, PAF Base Faisal, Karachi, 16 months (October 2019 to January 2021).

Patients and Methods:

The study included all patients requiring skin biopsies, except punch and shave biopsies. The procedure was done under strict aseptic measures in a dedicated room of the operation theatre, according to the standard protocol, and the patients were followed up for any surgical site infection. Demographic data of the patients along with other parameters, including comorbid conditions, presence or absence of surgical site infection, site of biopsy, type of biopsy, and type of sutures applied were recorded for each patient by direct observation. Data were analyzed using SPSS version 18.

Results:

One hundred and fifty-one patients, with a mean age of 36 ± 14 years, were included in the study. Out of 151 patients, 99(65.6%) were males and 52 (34.4%) were females. Excisional biopsy was done in 58 (38.4%) and incisional biopsy in 93 (61.6%)patients. The most commonly biopsied site was the trunk (45 patients). Wound infection was present in 04 patients. Two out of the 04 infected patients had diabetes mellitus and 01 was a smoker.

Conclusion:

Effective aseptic measures reduce surgical site infections in skin biopsy procedures.

How to cite this article

Piracha ZZ, Saeed U, Azam N. Unveiling Alpha-Naphthoflavone Mediated CYP1A2 Suppression and Analysis of Consequent Structural Dynamics. HMDJ. 2024; 04(01): 16-20.

DOI: https://doi.org/10.69884/hmdj.4.2.9820

References

Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive ffect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.Clin Pharmacol Ther. 2004;76(6):598–606.
Vasanthanathan P, Taboureau O, Oostenbrink C, et al. lassification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques. Drug Metabolism and Disposition. 2009; 37 (3) 658-664.
P05177 · CP1A2_HUMAN [Internet].Cambridgeshire(CB): Elixir, Welcome Genome Campus Hixton.[cited 2024 Feb 26]. Available from http://www.uniprot.org/uniprot/P05177.
Nebert DW,Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002; 360(9340):1155-1162.
Xu J. The effect of the new media on increasing female appearance anxiety. J Educ Humanit Soc Sci. 2023;8(2):1373-1377.
Bauer E, Guo Z, Ueng YF Bell, et al, P. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. . Chem Res Toxicol. 1995;8(1):136-42.
Shimada T, Yamazaki H, Foroozesh M, et al. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol. 1998;11(9):1048–1056.
Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008;9(5):625–37.
Zhou SF, Wang, B, Yang, LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010; 42(2): 268–354.
Ikeya K, Jaiswal AK, Owens RA, et al. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol. 1989;3(9):1399–1408.
Lewis DF, Lake BG, Dickins M, et al. Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica. 2003;33(3):239–254.
Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1-2):83–448.
Parker AC, Preston T, Heaf D, et al. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol. 1994;38(6):573–576.
Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev.1981;12(2): 221–237.
Shimizu T, Tateishi T, Hatano M,et al. Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase. J Biol Chem. 1991;266(6):3372–3375.
Smith DA, Ackland MJ, Jones BC, et al. Properties of cytochrome P450 isoenzymes and their substrates part 2: properties of cytochrome P450 substrates. Drug Discov Today. 1997;2(11):479 – 486.
Saeed U, Waheed Y, Anwar A, et al . In-Silico Binding of ATP to Protein Kinase C Delta: Insights into the Structure and Active Site. Eur J Sci Res.2011; 52 (2) :177-187.
Liu J, Ericksen SS, Sivaneri M, et al. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys. 2004;424(1):33–43.
Zhou SF, Yang LP, Zhou ZW, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. APPS J. 2009;11(3):481-494.
Sansen S, Yano JK, Reynald RL, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem. 2007;282(19):14348-14355.
Cho US, Park EY, Dong MS, et al. Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta. 2003;1648(1-2):195–202.

PDF